Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVE: Oleogel-S10 in Japanese patients with epidermolysis bullosa
jRCT2011240064Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Birch bark extract in junctional epidermolysis bullosa (JEB) and dystrophic epidermolysis bullosa (DEB), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Incidence of complete closure of the target wounds within 45 days of treatment. Started May 2025; status: recruiting.
02
Drugs
Birch bark extract
03
Conditions
junctional epidermolysis bullosa (JEB)dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on jRCT2011240064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240064.